O.A. Chernichenko, V.S. Sakalo
External beam radiation therapy of prostate cancer (review)
Objective: To assess the results of treatment of non-metastatic prostate cancer by radiotherapy, the role of new technologies, including 3D conformal radiation therapy (3DCRT) and hormonal therapy in combination with radiotherapy. Materials and methods: analysis of current research articles about the role of radiation therapy in the treatment of non-metastatic prostate cancer. Results. Comparing the results demonstrated a consistent reduction of biochemical no evidence disease-control (bNED) with increasing initial PSA. 7-year data of 5 leading
U.S. cancer centers indicate increased rates of bNED control, especially for patients with initial PSA levels above 10ng/ml using high doses. Statistically significant increase bNED control, lack of distant metastases, local progression and specific survival rates were observed in patients receiving long-term adjuvant hormone therapy, opposed to short. Conclusions. External beam radiation therapy remains an important method for treating patients with prostate cancer. Results of treatment of radiation dose > 70Gy show an increase bNED depending on the initial PSA level of difference is almost 30% compared with conventional dose of radiation (< 70Gy). However, with increasing initial PSA level bNED decreases. Implementation of 3DCRT multileaf collimator allows to increase the therapeutic dose of radiation therapy to the prostate. Simultaneously this method allowed to reduce the amount of healthy tissue that receives a significant dose of radiation, which reduces complications.